Compare · DXCM vs PYPD
DXCM vs PYPD
Side-by-side comparison of DexCom Inc. (DXCM) and PolyPid Ltd. (PYPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PYPD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.81B, about 232.6x PYPD ($128.2M).
- Over the past year, DXCM is up 37.5% and PYPD is up 74.6% - PYPD leads by 37.1 points.
- DXCM has been more active in the news (14 items in the past 4 weeks vs 6 for PYPD).
- DXCM has more recent analyst coverage (25 ratings vs 7 for PYPD).
- Company
- DexCom Inc.
- PolyPid Ltd.
- Price
- $80.31+0.51%
- $6.57+6.40%
- Market cap
- $29.81B
- $128.2M
- 1M return
- -7.01%
- +33.30%
- 1Y return
- +37.47%
- +74.60%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2020
- News (4w)
- 14
- 6
- Recent ratings
- 25
- 7
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
Latest PYPD
- PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
- Oppenheimer initiated coverage on PolyPid Ltd. with a new price target
- PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
- PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
- SEC Form 6-K filed by PolyPid Ltd.